Hypertension in Women

Uday M. Jadhav¹, Vaidehi S. Khilari²

¹Department of Cardiology and CV Imaging, MGM New Bombay Hospital, Navi Mumbai, Maharashtra, ²Department of Internal Medicine, MGM New Bombay Hospital, Navi Mumbai, Maharashtra

Abstract

Hypertension (HTN) in women has generated more focus in view of reports of increased prevalence. Women compared with men exhibit a steeper increase in blood pressure (BP) as early as in the third decade and continue in a linear time course thereafter. HTN is the most common medical disorder during pregnancy. Pre-existing HTN is defined as HTN diagnosis before pregnancy, early in pregnancy (before 20 weeks of gestation), or HTN continues after 6 weeks postpartum. Gestational hypertension (GH) is defined as HTN first diagnosis during pregnancy after 20 weeks of gestation. Antihypertensive medications should be initiated at BP ≥150/95 mmHg for patients with pre-existing HTN and >140/90 mmHg for patients with gestational HTN with or without proteinuria. BP target should be <140/90 for all hypertensive pregnant women. Women who take antihypertensive treatments other than ACE inhibitors, ARBs, thiazide or thiazide-like diuretics, and limited evidence available have not shown an increased risk of congenital malformation with such treatments. Labetalol is first-line medication during pregnancy and lactation. Antihypertensives should be restarted after delivery and tapered slowly only after days 3–6 postpartum. Most antihypertensive medicines taken while breastfeeding is safe. Women with established strong clinical risk factors for preeclampsia should be treated ideally before 16 weeks with low-dose aspirin 75–162 mg/day. Women with GH or preeclampsia have increased risks of cardiovascular disease and recurrence of preeclampsia and GH in future pregnancies.

Key words: Gestational hypertension, hypertension during pregnancy, hypertension, labetalol, preeclampsia, proteinuria

Introduction

The prevalence of hypertension (HTN) in women is an increasing concern. Data from 5,26,336 participants aged 40–79 years in the high-income countries have shown a prevalence of HTN across all women participants aged 40–79 years from 33% to 52%. In the age group of 40–49 years, HTN prevalence ranged from 12% to 20% and in 70–79 years from 61% to 82%.¹

Blood pressure (BP) was recorded for 180,335 participants with a mean age 40.6 ± 14.9 years in India which included 33.2% of women. The prevalence among women was 23.7%. Higher predisposition was noted during the menopausal age. In the age group of 45–54 years, the prevalence of HTN was 34.6% with systolic blood pressure (SBP) of 126.7 ± 18.0 mmHg and diastolic blood pressure (DBP) of 80.3 ± 10.9 mmHg.²⁻³

HTN in Women

Sympathetic activity, increased arterial stiffness may play an important role in the increased prevalence of HTN after menopause.⁴⁻⁵ Women with HTN are noted to develop more heart failure with preserved ejection fraction (HFrEF), atrial fibrillation, and dementia compared to men.⁶⁻⁷

Gender-specific analysis of existing data of four community cohort studies in 32,833 individuals over four decades and inclusive of 54% of women done recently has brought forth some important information on the trajectories of BP elevation. Women compared with men exhibited a steeper increase in BP that began as early as in the third decade and continued through the life course (likelihood ratio test $\chi^2 = 531$ for systolic BP; $\chi^2 = 123$ for diastolic BP; $\chi^2 = 325$ for mean arterial pressure [MAP]; and $\chi^2 = 572$ for PP; for all $P < 0.001$). MAP which is a vascular marker of small artery function also had a greater increase in women as they aged.⁸

Address for correspondence:
Dr. Uday M. Jadhav, Department of Internal Medicine, MGM New Bombay Hospital, Sector 3, Vashi, Navi Mumbai - 400 614, India.
E-mail: umjadhav@gmail.com

Received: 15-05-2020; Accepted: 28-05-2020
doi: 10.15713/ins.johtn.0186
Considering the assumption that vascular physiology may or may not fundamentally differ between women and men, these data revealed the early onset and more rapid progress of high BP in women and the manifestations of cardiovascular diseases in their later life.

Underlying genetic expression at the cellular level is a plausible hypothesis.[9]

Hypertensive Disease of Pregnancy (HDP)

HTN is the most common medical disorder during pregnancy, with a prevalence of 5–10% of all pregnancies worldwide.[10]

The discussion in the further text is based on the guidelines of American College of Obstetricians and Gynecologists, ESC/ESH guidelines, ISHHP guidelines, and the NICE guidelines[11–14] for the benefits of healthcare professionals. The discussion is mainly pertinent to HTN and BP lowering drugs and not on other pregnancy-related complications including eclampsia, which is beyond the purview of this article.

Classification of HDP

European guidelines have classified the severity of hypertension as mild HTN (SBP 140–159 mmHg and/or DBP 90–109 mmHg) and severe HTN (BP ≥160/110 mmHg). Classification of hypertension during pregnancy is described in Table 1.

Aneroid devices are used commonly for BP measurement, but they may be inaccurate and need to be regularly calibrated. In a smaller study, 50% of aneroid devices had at least 1 BP reading >10 mmHg out of range compared with the same error in only 10% of mercury devices.[15]

Diagnosis of HTN during pregnancy is based on the standard office BP measurements. Standard procedure for measurement of BP in pregnancy is described in Table 2. Ambulatory blood pressure monitoring (ABPM) which is an important tool in diagnosis and outcome studies in clinical practice[16] is not recommended because they may record lower BP readings and are unreliable in preeclampsia.[17] Also, the diagnosis of hypertension in the ambulatory phase relies on the non–outcome-derived cutoffs from normotensive pregnancies, or the defined threshold values in non-pregnant adults. Paucity of prospective multi-centric studies in different ethnicities of adequate sample size and ABPM outcome-derived thresholds makes ABPM recommendations difficult in HDP. With ongoing studies and data generation ABPM role in pregnancy should not be undermined.

Twenty-four hours ABPM or home BP monitoring has a utility in confirming office or clinic HTN after repeated measurements over hours at the same visit or on two consecutive antenatal visits to eliminate a diagnosis of white coat HTN. Normal values for 24 h ABPM in pregnancy have been determined.[18] Before 22 weeks, BP values should be below: 24 h average 126/76 mmHg; awake average BP 132/79 mmHg; and sleep average BP 114/66 mmHg. These values are slightly lower than those used as thresholds for diagnosing HTN in non-pregnant women.

ISSHP does not recommend routine testing for any secondary cause of HTN in the absence of clinical clues to these conditions as they are less common.

Complications of Hypertension during Pregnancy are described in Table 3. Eclampsia is a severe form of preeclampsia associated with generalized tonic-clonic seizures. Preeclampsia may develop in the early postpartum period in few cases. If women with chronic HTN are suspected of developing preeclampsia,

Table 1: Classification of hypertension

| Classification of HDP | HTN diagnosis before pregnancy, early in pregnancy (before 20 weeks of gestation), or HTN continues after 6 weeks postpartum. |
|----------------------|------------------------------------------------------------------------------------------------------------------|
| Preexisting hypertension | Gestational hypertension |
| Preexisting hypertension plus superimposed gestational hypertension with proteinuria | Preeclampsia |
| Antenatally unclassifiable hypertension | Antenatally unclassifiable hypertension |
| HTN diagnosis after 20 weeks of gestation and it is unclear if hypertension was preexisting and reassessed after 6 weeks postpartum. | HTN: Hypertension |

Table 2: Blood pressure measurement and HDP

| Blood pressure measurement and HDP | Defined as systolic BP ≥140 and/or diastolic BP ≥90 mmHg. BP should be repeated to confirm true hypertension |
|----------------------------------|-------------------------------------------------------------------------------------------------------------|
| BP should be confirmed within 15 min if systolic BP ≥160 and/or diastolic BP ≥110 mmHg | BP to be measured with a liquid crystal sphygmomanometer and if unavailable, validated and appropriately calibrated automated device |
| Correct cuff size is important, large cuff to be used if the mid upper arm circumference is >33 cm | HDP: Hypertensive disease of pregnancy, BP: Blood pressure |

Table 3: Complications of hypertension during pregnancy

| Complications of hypertension during pregnancy | Preeclampsia |
|-----------------------------------------------|-------------|
| HELLP syndrome (hemolysis, elevated liver enzymes, and a low platelet count) | Disseminated intravascular coagulation. |
| Placental abruption | Intrauterine growth retardation (25% cases of preeclampsia) |
| Disseminated intravascular coagulation. | Prematurity (27% cases of preeclampsia) |
| Intrauterine growth retardation (25% cases of preeclampsia) | Intrauterine death (4% cases of preeclampsia) |
| Prematurity (27% cases of preeclampsia) | Chronic hypertension (4-fold higher risk) |
| Intrauterine death (4% cases of preeclampsia) | Stroke and ischemic heart diseases (2-fold higher risk) |
| Chronic hypertension (4-fold higher risk) | Preterm delivery (12.5% in women with gestational hypertension) |
placental growth factor-based testing is recommended to help rule out preeclampsia between 20 weeks and up to 35 weeks of pregnancy.

**Principles of antihypertensive therapy**

Antihypertensive medications should be initiated at BP ≥150/95 mmHg for patients with preexisting HTN and >140/90 mmHg for patients with gestational HTN (with or without proteinuria) and patients with subclinical HTN-mediated organ damage.

BP target should be <140/90 for all hypertensive pregnant women. Physiological drop of BP is noted in the second trimester and some pregnant women may require reduction of dose or sometimes withdrawal of their antihypertensive medication. It is desirable to maintain BP 110–140/85 mmHg.

CHIPS trial (control of HTN in pregnancy study) studied the effects of tight control of BP (DBP <85 mmHg and SBP <160 mmHg). Diastolic BP of 85 mmHg was associated with reduced likelihood of developing accelerated maternal HTN and no demonstrable adverse outcome for babies compared with targeting higher diastolic BP in the CHIPS trial in chronic hypertensive women.[19]

Development of severe HTN was associated with significantly greater likelihood of adverse outcomes in the mother (thrombocytopenia, abnormal liver enzymes with symptoms, and longer hospital stay) and neonate (low birth weight, prematurity, death, and morbidity requiring neonatal unit care) in the follow-up of women in the CHIPS trial. Severe HTN in the less tight control was associated with significantly more serious maternal complications.[20]

Cochrane review on antihypertensive therapy for mild-to-moderate HTN during pregnancy (BP 140–169 mmHg/90–109 mmHg) found that initiating treatment halved the risk of progression to severe HTN but had no effect on the risk of preeclampsia.[21]

**Drug therapy for mild HTN**

Rigorous salt restriction and weight loss are not recommended during pregnancy due to the risk of volume contraction and neonatal growth restriction, respectively.[22,23] Recent reexamination of the high-risk aspirin trial data during pregnancy reported that the newly identified Stage 1 HTN in pregnancy was associated with increased risk of preeclampsia compared with normotensive women (39% vs. 15%) and that randomization to aspirin reduced this risk (24% vs. 39%).[24]

ISSHP recommends that women with established strong clinical risk factors for preeclampsia (i.e., prior preeclampsia, chronic HTN, pregestational diabetes mellitus, maternal body mass index >30 kg/m², antiphospholipid syndrome, and receipt of assisted reproduction) be treated, ideally before 16 weeks but definitely before 20 weeks, with low-dose aspirin (defined as 75–162 mg/day, as studied in randomized controlled trials). Pre-pregnancy advice for BP lowering drugs in women is described in Table 4.

**Table 4: Pre-pregnancy advice for blood pressure lowering drugs**

ACE inhibitors or ARBs are associated with an increased risk of congenital abnormalities if taken during pregnancy

ACE inhibitors or ARBs should be stopped preferably within 2 working days of notification of pregnancy

Thiazide or thiazide-like diuretics may have an increased risk of congenital abnormalities and neonatal complications

Antihypertensive treatments other than ACE inhibitors, ARBs, thiazide, or thiazide-like diuretics have not been shown to have an increased risk of congenital malformation

Pregnancy and lactation labeling rule system must be checked before prescribing any drugs to pregnant women. BP lowering drugs and drugs for urgent BP control are described in Tables 5 and 6 respectively. Acceptable initial antihypertensives include labetalol, oxprenolol, methyldopa, nifedipine, diltiazem, prazosin, and hydralazine are usually used as the second- or third-line agents. Atenolol should be avoided in pregnancy as it is associated with fetal growth impairment and this effect is related to duration of therapy. Recent studies suggest that exposure to ACEI early in pregnancy during the period of organogenesis does not confer an increase in the risk of malformations.[25]

**Timing of birth and intrapartum antihypertensive treatment**

Women with preeclampsia should be delivered if they have reached 37 weeks’ (and 0 days) gestation or if they develop repeated episodes of severe HTN despite maintenance treatment with three classes of antihypertensive agents (ISSHP). Planned early birth before 37 weeks is not recommended to women with chronic HTN whose BP is lower than 160/110 mmHg, with or without antihypertensive treatment, unless there are other medical indications. For women with chronic HTN, whose BP is lower than 160/110 mmHg after 37 weeks, with or without antihypertensive treatment, timing of birth, and maternal and fetal indications for birth should be agreed between the woman and the senior obstetrician. If planned early birth is necessary, antenatal corticosteroids and magnesium sulfate, if indicated, may be given in line with the NICE guideline on preterm labor and birth.

Oral antihypertensives should be given at the start of labor. HTN should be treated urgently with oral nifedipine or either intravenous labetalol or hydralazine if BP rises ≥160/110 mmHg. Total fluid intake should be limited to 60–80 mL/h. Absorption of antihypertensives after oral administration can be hampered because of reduced gastrointestinal motility. Intravenous antihypertensives may be needed to control severe HTN. Short term and long term measures in the post partum phase are described in Table 7.

**Antihypertensive treatment during lactation**

Antihypertensive medicines can pass into breast milk. Most antihypertensive medicines taken while breastfeeding only lead to very low levels in breast milk, so the amounts taken in by babies are very small and would be unlikely to have any
Most medicines are not tested in pregnant or breastfeeding women, so disclaimers in the manufacturer’s information are not because of any specific safety concerns or evidence of harm. Methyldopa should be avoided because of the risk of postpartum depression.

Angiotensin-converting enzyme inhibitors captopril and enalapril are considered safe given their low concentrations in breast milk. Enalapril can be offered to treat HTN in women during the postnatal period, with appropriate monitoring of maternal renal function and maternal serum potassium. Calcium channel blockers have a limited data and nifedipine is commonly used during breastfeeding. Diuretics are discouraged because of the risk of reducing breast milk production.

### HTN in Pregnancy – Future Cardiovascular Implications

Progression to chronic HTN postpartum has been reported in 42% of women with preeclampsia and 39% of women with gestational hypertension (GH) after mean follow-up of 2.5 years as compared to 1% among women with normotensive pregnancies.[31] Women with GH or preeclampsia should be advised that they have increased risks of cardiovascular disease, death, stroke, diabetes mellitus, venous thromboembolic disease, and CKD compared with women who have had normotensive pregnancies.[32,33]

Women with a history of preeclampsia have 71% increased risk of CV mortality, a 2.5-fold increase in risk of coronary artery disease (CAD), and a 4-fold increase in the development of heart failure when compared to normal cohorts as shown in a recent meta-analysis.[34,35] Nurse’s Health Study II reported that women with GH and pre-eclampsia had a 3-fold and 6-fold increased rate of chronic HTN. Women with HTN during their first pregnancy had 70% increased risk of type 2 diabetes and 30% increased prevalence of hypercholesterolemia later in life.[36] Norwegian study with a mean follow-up of 17.2 years found that women with preeclampsia alone had a 2-fold increased risk of a major CV event.[37]

### Table 5: Antihypertensive drugs during pregnancy

| Drug | Recommended | Dose | Side effects/concerns |
|------|-------------|------|------------------------|
| Labetalol | Yes (first choice) | 100–200 mg bid, maximum 1200 mg in four doses | Fetal bradycardia or intrauterine growth retardation |
| Alpha methyl dopa | Yes | 0.5–3.0 g in 2–4 doses | Sleepiness, dry mouth, general malaise, hemolytic anemia, and hepatopathy[24] |
| Calcium channel blockers, for example, nifedipine | Yes | 20–120 mg long-acting single dose | Headache, pedal edema, dizziness |
| Hydralazine | Yes | 40–200 mg/day in up to four doses | Fetal thrombocytopenia Reflex sympathetic activation |
| Thiazide and potassium-sparing diuretics | No | -- | Potential risk of oligohydramnios |
| ACEIs and ARBs | No | -- | Renal dysplasia, pulmonary hypoplasia, growth restriction[27] |

### Table 6: Drug therapy for urgent BP control[13]

| Drug | Dose | Side effects |
|------|------|--------------|
| Labetalol | 10–20 mg IV, then 20–80 mg every 10–30 min to a maximum cumulative dosage of 300 mg; or constant infusion 1–2 mg/min IV; onset of action 1–2 min | Bradycardia |
| Hydralazine | 5 mg IV or IM, then 5–10 mg IV every 20–40 min maximum dose 20 mg; or constant infusion of 0.5–10 mg/h; onset of action 10–20 min | Maternal hypotension, headaches, and abnormal fetal heart rate tracings |
| Nifedipine immediate release | 10–20 mg orally, repeat in 20 min if needed; then 10–20 mg every 2–6 h; maximum daily dose is 180 mg; onset of action 5–10 min | Tachycardia, headache |

### Table 7: Postpartum follow-up – short term and long term

Blood pressure should be monitored at least every 4 h while awake in view of high risk for preeclamptic complications for the first 3 days. Antihypertensives administered antenatally should be continued and withdrawn slowly over 3–6 days. Antihypertensive therapy may be given for any hypertension before day 6 postpartum. Review recommended at 3 months postpartum by which time BP, urinalysis, and all laboratory tests should have normalized. Women with gestational hypertension should be advised that they have approximately a 4% risk for developing preeclampsia.[28,30]
Conclusions

High-income countries have reported prevalence of HTN in women aged 40–79 years from 33% to 52% and in India of 23.7%. Higher predisposition is noted during the menopausal age. Vascular physiology may or may not fundamentally differ between women and men but recent evidence has focused on the early onset and more rapid progress of high BP in women and the manifestations of cardiovascular diseases in their later life. HDP which includes all the entities preeclampsia, GH, and chronic HTN is associated with significantly increased risk of CVD in the first decade postpartum and in the long term.

HTN is the most common medical disorder during pregnancy, with a prevalence of 5–10% of all pregnancies worldwide. Progression to chronic HTN postpartum has been reported in close to half of women with preeclampsia and substantial number of women with GH. Women with a history of preeclampsia have a high risk of CV mortality, a 2.5-fold increase in risk of CAD, and a 4-fold increase in the development of heart failure. Labetalol, CCB’s, and methyldopa are safe drugs in HDP and ACE inhibitors, ARBs, thiazide, or thiazide-like diuretics are to be avoided. Women with HTN who need to take antihypertensive medication can be adapted to accommodate breastfeeding without any harm.

Acknowledgment

Sumendra Pawar for secretarial assistance.

References

1. NDC Risk Factor Collaboration (ncd-risC)-Americas Working Group. Trends in cardiometabolic risk factors in the Americas between 1980 and 2014: A pooled analysis of population-based surveys. Lancet Glob Health 2020;8:e123-33.
2. Jose AP, Prabhakaran D. World hypertension day: Contemporary issues faced in India. Indian J Med Res 2019;149:567-70.
3. Ramakrishnan S, Zachariah G, Gupta K, Rao JS, Mohanan PP. Prevalence of hypertension among Indian adults: Results from the great India blood pressure survey. Indian Heart J 2019;71:309-13.
4. Maas A. Hypertension in women: No “silent” lady-killer. E J Cardiol Pract 2019;17:11-21.
5. Barnes JN, Hart EC, Curry TB, Nicholson WT, Eisenach JH, Wallin BG, et al. Aging enhances autonomic support of blood pressure in women. Hypertension 2014;63:303-8.
6. Beale AL, Meyer P, Marwick TH, Lam CS, Kaye DM. Sex differences in cardiovascular pathophysiology: Why women are overrepresented in heart failure with preserved ejection fraction. Circulation 2018;138:198-205.
7. Wenger NK, Arnold A, Merz CN, Cooper-DeHoff RM, Ferdinand KC, Fleg JL, et al. Hypertension across a woman’s life cycle. Am Coll Cardiol 2018;71:1797-813.
8. Ji H, Kim A, Ebinge JE, Niiranen TJ, Claggett BL, Merz CN, et al. Sex differences in blood pressure trajectories over the life course. JAMA Cardiol 2020;5:19-26.
9. Wenger NK. Adverse cardiovascular outcomes for women: Biology, bias, or both? JAMA Cardiol 2020;5:26.
10. Youssef GS. Hypertension in pregnancy. E J Cardiol Pract 2019;17:18-22.
11. American College of Obstetricians and Gynecologists; Task Force on Hypertension in Pregnancy. Hypertension in pregnancy. Report of the American college of obstetricians and gynecologists’ task force on hypertension in pregnancy. Obstet Gynecol 2013;122:1122-31.
12. Regitz-Zagrosek V, Roos-Hesselink JW, Bauersachs J, Blomstrom-Lundqvist C, Cilikoova R, De Bonis M, et al. 2018 ESC guidelines for the management of cardiovascular diseases during pregnancy. Eur Heart J 2018;39:3165-241.
13. Brown MA, Magee LA, Kenny LC, Karumanchil SA, McCarthy FP, Saito S, et al. Hypertensive disorders of pregnancy: ISSHP classification, diagnosis, and management recommendations for international practice. Hypertension 2018;72:24-43.
14. Hypertension in Pregnancy: Diagnosis and Management. NICE guideline. Available from: http://www.nice.org.uk/guidance/ng133. [Last accessed on 2019 Jun 25].
15. Vaugh J, Gupta M, Rushbrook J, Halligan A, Shennan AH. Hidden errors of aneroid sphygmomanometers. Blood Press Monit 2002;7:309-12.
16. Tranquilli AL, Dekker G, Magee L, Roberts J, Sibai BM, Steyn W, et al. The classification, diagnosis and management of the hypertensive disorders of pregnancy: A revised statement from the ISSHP. Pregnancy Hypertens 2014;4:97-104.
17. Tranquilli AL, Brown MA, Zeeman GG, Dekker G, Sibai BM. The definition of severe and early-onset preeclampsia. Statements from the international society for the study of hypertension in pregnancy (ISSHP). Pregnancy Hypertens 2013;3:44-7.
18. Brown MA, Robinson A, Bowyer L, Buddle ML, Martin A, Hargood JL, et al. Ambulatory blood pressure monitoring in pregnancy: What is normal? Am J Obstet Gynecol 1998;178:836-42.
19. Magee LA, von Dadelszen P, Rey E, Ross S, Asztalos E, Murphy KE, et al. Less-tight versus tight control of hypertension in pregnancy. N Engl J Med 2015;372:407-17.
20. Magee LA, von Dadoszen P, Singer J, Lee T, Rey E, Ross S, et al. The CHIPS randomized controlled trial (control of hypertension in pregnancy study): Is severe hypertension just an elevated blood pressure? Hypertension 2016;68:1153-9.
21. Abalos E, Duley L, Steyn DW. Antihypertensive drug therapy for mild to moderate hypertension during pregnancy. Cochrane Database Syst Rev 2018;10:CD002252.
22. Semlitsch T, Jeiter K, Berghold A, Horvath K, Posch N, Poggenburg S, et al. Long-term effects of weight-reducing diets in people with hypertension. Cochrane Database Syst Rev 2016;3:CD008274.
23. Blumenthal JA, Babjak MA, Hinderliter A, Watkins LL, Craighead L, Lin PH, et al. Effects of the DASH diet alone and in combination with exercise and weight loss on blood pressure and cardiovascular biomarkers in men and women with high blood pressure: The ENCORE study. Arch Intern Med 2010;170:126-35.
24. Hauspurg A, Youssef GS. Hypertension in pregnancy. E J Cardiol Pract 2014;6:2
25. Bateman BT, Patorno E, Desai RJ, Seely EW, Mogun H, Dejene SZ, et al. Angiotensin-converting enzyme inhibitors and the risk of congenital malformations. Obstet Gynecol 2017;129:174-84.
26. Leavitt K, Obican S, Yankowitz J. Treatment and prevention
of hypertensive disorders during pregnancy. Clin Perinatol 2019;46:173-85.
27. Kaye AB, Bhakta A, Moseley AD, Rao AK, Arif S, Lichtenstein SJ, et al. Review of cardiovascular drugs in pregnancy. J Womens Health (Larchmt) 2019;28:686-97.
28. Brown MA, Mackenzie C, Dunsmuir W, Roberts L, Ikin K, Matthews J, et al. Can we predict recurrence of pre-eclampsia or gestational hypertension? BJOG 2007;114:984-93.
29. Beardmore KS, Morris JM, Gallery ED. Excretion of antihypertensive medication into human breast milk: A systematic review. Hypertens Pregnancy 2002;21:85-95.
30. Gongora MC, Sharma G, Yang E. Hypertension during pregnancy and after delivery: Management, cardiovascular outcomes and future directions. J Am Coll Cardiol 2018;71:127-248.
31. Ying W, Catov JM, Ouyang P. Hypertensive disorders of pregnancy and future maternal cardiovascular risk. J Am Heart Assoc 2018;7:e009382.
32. Theilen L, Meeks H, Fraser A, Esplin MS, Smith KR, Varner M. Long-term mortality risk and life expectancy following recurrent hypertensive disease of pregnancy. Am J Obstet Gynecol 2017;216:S32-3.
33. Toomer J, Thornton C, Makris A, Ogle R, Korda A, Horvath J, et al. Hypertension in pregnancy and long-term cardiovascular mortality: A retrospective cohort study. Am J Obstet Gynecol 2016;214:722.e1-6.
34. Wu P, Hathhoto U, Kwok CS, Babu A, Kotronias RA, Rushton C, et al. Preeclampsia and future cardiovascular health: A systematic review and meta-analysis. Circ Cardiovasc Qual Outcomes 2017;10: e003497.
35. McDonald SD, Malinowski A, Zhou Q, Yusuf S, Devereaux PJ. Cardiovascular sequelae of preeclampsia/eclampsia: A systematic review and meta-analyses. Am Heart J 2008;156:918-30.
36. Stuart JJ, Tanz LJ, Misser SA, Rimm EB, Spiegelman D, James-Todd TM, et al. Hypertensive disorders of pregnancy and maternal cardiovascular disease risk factor development: An observational cohort study. Ann Intern Med 2018;169:224-32.
37. Riise HK, Sulo G, Tell GS, Iglund J, Nygard O, Vollset SE, et al. Incident coronary heart disease after preeclampsia: Role of reduced fetal growth, preterm delivery, and parity. J Am Heart Assoc 2017;6:e004158.